Does the media prefer OCS or MLYS?

In the previous week, Mineralys Therapeutics had 4 more articles in the media than Oculis. MarketBeat recorded 10 mentions for Mineralys Therapeutics and 6 mentions for Oculis. Oculis' average media sentiment score of 1.02 beat Mineralys Therapeutics' score of 0.30 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, PRGO or OCS?

Oculis has lower revenue, but higher earnings than Perrigo. Oculis is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Perrigo $4.25B 0.50 -$1.43B -$12.51 N/A Oculis $1.45M 304.69 -$119.44M -$1.74 N/A

Is PRGO or OCS more profitable?

Perrigo has a net margin of -41.85% compared to Oculis' net margin of -6,777.18%. Perrigo's return on equity of 11.25% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Perrigo -41.85% 11.25% 4.08% Oculis -6,777.18% -42.61% -35.23%

Does the media refer more to PRGO or OCS?

In the previous week, Perrigo and Perrigo both had 6 articles in the media. Oculis' average media sentiment score of 1.02 beat Perrigo's score of 0.73 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is OCS or TRVI more profitable?

Trevi Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -6,777.18%. Trevi Therapeutics' return on equity of -23.59% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -6,777.18% -42.61% -35.23% Trevi Therapeutics N/A -23.59% -22.64%

Does the media prefer OCS or TRVI?

In the previous week, Oculis had 4 more articles in the media than Trevi Therapeutics. MarketBeat recorded 6 mentions for Oculis and 2 mentions for Trevi Therapeutics. Oculis' average media sentiment score of 1.02 beat Trevi Therapeutics' score of 0.95 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to OCS or GPCR?

In the previous week, Oculis had 4 more articles in the media than Structure Therapeutics. MarketBeat recorded 6 mentions for Oculis and 2 mentions for Structure Therapeutics. Oculis' average media sentiment score of 1.02 beat Structure Therapeutics' score of -0.09 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation & earnings, OCS or XERS?

Xeris Biopharma has higher revenue and earnings than Oculis. Xeris Biopharma is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis $1.45M 304.69 -$119.44M -$1.74 N/A Xeris Biopharma $291.85M 6.37 $550K -$0.11 N/A

Is OCS or XERS more profitable?

Xeris Biopharma has a net margin of -5.12% compared to Oculis' net margin of -6,777.18%. Xeris Biopharma's return on equity of 338.21% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -6,777.18% -42.61% -35.23% Xeris Biopharma -5.12% 338.21% 3.50%

Does the media prefer OCS or XERS?

In the previous week, Oculis had 3 more articles in the media than Xeris Biopharma. MarketBeat recorded 6 mentions for Oculis and 3 mentions for Xeris Biopharma. Oculis' average media sentiment score of 1.02 beat Xeris Biopharma's score of 0.89 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oculis (OCS) Competitors

$7.49 -0.13 (-1.71%)

As of 11:01 AM Eastern

Compare

OCS vs. MLYS, PRGO, TRVI, GPCR, and XERS

Should you buy Oculis stock or one of its competitors? Oculis's main competitors and comparable companies include Mineralys Therapeutics (MLYS), Perrigo (PRGO), Trevi Therapeutics (TRVI), Structure Therapeutics (GPCR), and Xeris Biopharma (XERS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Oculis compare to Mineralys Therapeutics?

Oculis (NASDAQ:OCS) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Oculis presently has a consensus price target of $39.44, indicating a potential upside of 417.64%. Mineralys Therapeutics has a consensus price target of $45.50, indicating a potential upside of 116.67%. Given Oculis' stronger consensus rating and higher probable upside, analysts plainly believe Oculis is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Mineralys Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

22.3% of Oculis shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 18.9% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Mineralys Therapeutics had 4 more articles in the media than Oculis. MarketBeat recorded 10 mentions for Mineralys Therapeutics and 6 mentions for Oculis. Oculis' average media sentiment score of 1.02 beat Mineralys Therapeutics' score of 0.30 indicating that Oculis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Mineralys Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Oculis has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	304.69	-$119.44M	-$1.74	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A

Oculis has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

Mineralys Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -6,777.18%. Oculis' return on equity of -42.61% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-6,777.18%	-42.61%	-35.23%
Mineralys Therapeutics	N/A	-57.97%	-54.15%

Summary

Oculis beats Mineralys Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Oculis compare to Perrigo?

Perrigo (NYSE:PRGO) and Oculis (NASDAQ:OCS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Oculis has lower revenue, but higher earnings than Perrigo. Oculis is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.50	-$1.43B	-$12.51	N/A
Oculis	$1.45M	304.69	-$119.44M	-$1.74	N/A

Perrigo currently has a consensus price target of $19.33, suggesting a potential upside of 25.91%. Oculis has a consensus price target of $39.44, suggesting a potential upside of 417.64%. Given Oculis' stronger consensus rating and higher possible upside, analysts plainly believe Oculis is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Perrigo has a net margin of -41.85% compared to Oculis' net margin of -6,777.18%. Perrigo's return on equity of 11.25% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-41.85%	11.25%	4.08%
Oculis	-6,777.18%	-42.61%	-35.23%

In the previous week, Perrigo and Perrigo both had 6 articles in the media. Oculis' average media sentiment score of 1.02 beat Perrigo's score of 0.73 indicating that Oculis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oculis	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Perrigo has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, Oculis has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

95.9% of Perrigo shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 0.4% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Perrigo beats Oculis on 8 of the 15 factors compared between the two stocks.

How does Oculis compare to Trevi Therapeutics?

Oculis (NASDAQ:OCS) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Oculis had 4 more articles in the media than Trevi Therapeutics. MarketBeat recorded 6 mentions for Oculis and 2 mentions for Trevi Therapeutics. Oculis' average media sentiment score of 1.02 beat Trevi Therapeutics' score of 0.95 indicating that Oculis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Trevi Therapeutics has lower revenue, but higher earnings than Oculis. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	304.69	-$119.44M	-$1.74	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A

Oculis has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

Oculis currently has a consensus target price of $39.44, indicating a potential upside of 417.64%. Trevi Therapeutics has a consensus target price of $27.08, indicating a potential upside of 120.37%. Given Oculis' higher possible upside, research analysts clearly believe Oculis is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Trevi Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -6,777.18%. Trevi Therapeutics' return on equity of -23.59% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-6,777.18%	-42.61%	-35.23%
Trevi Therapeutics	N/A	-23.59%	-22.64%

22.3% of Oculis shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 15.4% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Trevi Therapeutics beats Oculis on 11 of the 15 factors compared between the two stocks.

How does Oculis compare to Structure Therapeutics?

Oculis (NASDAQ:OCS) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

22.3% of Oculis shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Oculis has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.3, meaning that its share price is 230% less volatile than the broader market.

Structure Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -6,777.18%. Structure Therapeutics' return on equity of -25.56% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-6,777.18%	-42.61%	-35.23%
Structure Therapeutics	N/A	-25.56%	-24.31%

Oculis has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	304.69	-$119.44M	-$1.74	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

Oculis presently has a consensus target price of $39.44, suggesting a potential upside of 417.64%. Structure Therapeutics has a consensus target price of $110.91, suggesting a potential upside of 397.13%. Given Oculis' higher probable upside, research analysts clearly believe Oculis is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82

In the previous week, Oculis had 4 more articles in the media than Structure Therapeutics. MarketBeat recorded 6 mentions for Oculis and 2 mentions for Structure Therapeutics. Oculis' average media sentiment score of 1.02 beat Structure Therapeutics' score of -0.09 indicating that Oculis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Structure Therapeutics beats Oculis on 9 of the 15 factors compared between the two stocks.

How does Oculis compare to Xeris Biopharma?

Oculis (NASDAQ:OCS) and Xeris Biopharma (NASDAQ:XERS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Oculis has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

22.3% of Oculis shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Xeris Biopharma has a net margin of -5.12% compared to Oculis' net margin of -6,777.18%. Xeris Biopharma's return on equity of 338.21% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-6,777.18%	-42.61%	-35.23%
Xeris Biopharma	-5.12%	338.21%	3.50%

Xeris Biopharma has higher revenue and earnings than Oculis. Xeris Biopharma is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	304.69	-$119.44M	-$1.74	N/A
Xeris Biopharma	$291.85M	6.37	$550K	-$0.11	N/A

Oculis currently has a consensus target price of $39.44, indicating a potential upside of 417.64%. Xeris Biopharma has a consensus target price of $13.20, indicating a potential upside of 29.41%. Given Oculis' stronger consensus rating and higher probable upside, analysts plainly believe Oculis is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Oculis had 3 more articles in the media than Xeris Biopharma. MarketBeat recorded 6 mentions for Oculis and 3 mentions for Xeris Biopharma. Oculis' average media sentiment score of 1.02 beat Xeris Biopharma's score of 0.89 indicating that Oculis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Oculis and Xeris Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

Get Oculis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCS vs. The Competition

Export

Metric	Oculis	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$435.43M	$12.35B	$7.25B	$13.04B
Dividend Yield	N/A	2.63%	2.52%	22.89%
P/E Ratio	-4.32	807.81	275.44	25.51
Price / Sales	299.50	748.69	562.05	79.58
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	1.84	9.26	10.64	6.00
Net Income	-$119.44M	$2.83B	$3.49B	$380.50M
7 Day Performance	-11.88%	-3.62%	-3.21%	-3.35%
1 Month Performance	-29.34%	-7.66%	-7.65%	-6.23%
1 Year Performance	-65.23%	-5.44%	2.92%	-3.96%

Oculis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCS Oculis	2.1129 of 5 stars	$7.49 -1.7%	$39.44 +426.6%	-63.7%	$435.43M	$1.45M	N/A	60
MLYS Mineralys Therapeutics	3.6016 of 5 stars	$22.02 -5.5%	$48.80 +121.6%	-51.2%	$1.95B	N/A	N/A	76	Analyst Upgrade
PRGO Perrigo	3.3889 of 5 stars	$13.94 -3.4%	$19.33 +38.6%	-27.7%	$1.93B	$4.14B	N/A	8,100	News Coverage
TRVI Trevi Therapeutics	3.1034 of 5 stars	$13.28 -3.2%	$27.08 +104.0%	+26.6%	$1.89B	N/A	N/A	34	News Coverage
GPCR Structure Therapeutics	2.1762 of 5 stars	$26.99 -2.2%	$110.91 +310.9%	-26.1%	$1.88B	N/A	N/A	281

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCS) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oculis (OCS) Competitors

OCS vs. MLYS, PRGO, TRVI, GPCR, and XERS

How does Oculis compare to Mineralys Therapeutics?

Summary

How does Oculis compare to Perrigo?

Summary

How does Oculis compare to Trevi Therapeutics?

Summary

How does Oculis compare to Structure Therapeutics?

Summary

How does Oculis compare to Xeris Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS vs. The Competition

Oculis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oculis (OCS) Competitors

OCS vs. MLYS, PRGO, TRVI, GPCR, and XERS

How does Oculis compare to Mineralys Therapeutics?

Do analysts recommend OCS or MLYS?

Do insiders and institutionals believe in OCS or MLYS?

Does the media prefer OCS or MLYS?

Which has higher valuation & earnings, OCS or MLYS?

Which has more volatility and risk, OCS or MLYS?

Is OCS or MLYS more profitable?

Summary

How does Oculis compare to Perrigo?

Which has preferable earnings and valuation, PRGO or OCS?

Do analysts recommend PRGO or OCS?

Is PRGO or OCS more profitable?

Does the media refer more to PRGO or OCS?

Which has more risk and volatility, PRGO or OCS?

Do institutionals and insiders believe in PRGO or OCS?

Summary

How does Oculis compare to Trevi Therapeutics?

Does the media prefer OCS or TRVI?

Which has preferable earnings & valuation, OCS or TRVI?

Which has more risk & volatility, OCS or TRVI?

Do analysts rate OCS or TRVI?

Is OCS or TRVI more profitable?

Do insiders and institutionals believe in OCS or TRVI?

Summary

How does Oculis compare to Structure Therapeutics?

Do institutionals and insiders believe in OCS or GPCR?

Which has more volatility and risk, OCS or GPCR?

Is OCS or GPCR more profitable?

Which has preferable earnings and valuation, OCS or GPCR?

Do analysts rate OCS or GPCR?

Does the media refer more to OCS or GPCR?

Summary

How does Oculis compare to Xeris Biopharma?

Which has more volatility & risk, OCS or XERS?

Do institutionals & insiders have more ownership in OCS or XERS?

Is OCS or XERS more profitable?

Which has better valuation & earnings, OCS or XERS?

Do analysts recommend OCS or XERS?

Does the media prefer OCS or XERS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS vs. The Competition

Oculis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools